Hepatotoxicity of antiretrovirals: incidence, mechanisms and management (Q36008539)

11 August 2017

1 reference

title

Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. (English)

1 reference

11 August 2017

main subject

anti-retroviral agent

0 references

1 reference

2

Vincent Soriano

1 reference

11 August 2017

Marina Núñez

1

1 reference

11 August 2017

publication date

1 January 2005

1 reference

11 August 2017

1 reference

11 August 2017

volume

28

1 reference

11 August 2017

issue

1

1 reference

11 August 2017

page(s)

53-66

1 reference

Association of increased hepatitis C virus (HCV)-specific IgG and soluble CD26 dipeptidyl peptidase IV enzyme activity with hepatotoxicity after highly active antiretroviral therapy in human immunodeficiency virus-HCV-coinfected patients

11 August 2017

cites work

1 reference

12 December 2020

Jaundice and hepatocellular damage associated with nevirapine therapy

1 reference

12 December 2020

Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects

1 reference

12 December 2020

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

1 reference

12 December 2020

l-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues

1 reference

12 December 2020

Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1.

1 reference

12 December 2020

Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy

1 reference

12 December 2020

Drug-induced liver injury: mechanisms and test systems.

1 reference

12 December 2020

Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy

1 reference

12 December 2020

Hepatitis C virus and human immunodeficiency virus: clinical issues in coinfection

1 reference

12 December 2020

Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy

1 reference

12 December 2020

Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy

1 reference

12 December 2020

Severe hepatitis in patients with AIDS and haemophilia B treated with indinavir

1 reference

12 December 2020

Hepatitis C and HIV infection: biological, clinical, and therapeutic implications

1 reference

12 December 2020

Clinical practice. Occupational exposure to HIV in health care settings

1 reference

12 December 2020

Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases

1 reference

12 December 2020

Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999

1 reference

12 December 2020

Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference

1 reference

12 December 2020

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

1 reference

12 December 2020

Hepatotoxicity of antiretroviral therapy

1 reference

12 December 2020

Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection

1 reference

12 December 2020

Short communication: interactions between nevirapine plasma levels, chronic hepatitis C, and the development of liver toxicity in HIV-infected patients

1 reference

12 December 2020

A near-fatal hypersensitivity reaction to abacavir: case report and literature review

1 reference

12 December 2020

Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)

1 reference

12 December 2020

Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors

1 reference

12 December 2020

Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel.

1 reference

12 December 2020

Hepatotoxicity after prophylaxis with a nevirapine-containing antiretroviral regimen

1 reference

12 December 2020

Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine

1 reference

12 December 2020

Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases

1 reference

12 December 2020

Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy

1 reference

12 December 2020

Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus

1 reference

12 December 2020

Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection

1 reference

12 December 2020

Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy

1 reference

12 December 2020

Abacavir hypersensitivity reaction

1 reference

12 December 2020

Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy

1 reference

12 December 2020

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

12 December 2020

Riboflavin to treat nucleoside analogue-induced lactic acidosis

1 reference

12 December 2020

Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. Groupe dEpidémiologie Clinique de Sida en Aquitaine (GECSA)

1 reference

12 December 2020

Lack of hepatotoxicity associated with nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Type 1/Type 2 immunity in infectious diseases

1 reference

12 December 2020

Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections

1 reference

12 December 2020

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

12 December 2020

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.

1 reference

12 December 2020

Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.

1 reference

12 December 2020

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Idiosyncratic drug reactions: the reactive metabolite syndromes

1 reference

12 December 2020

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

1 reference

12 December 2020

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

12 December 2020

Acute hepatitis in HIV-infected patients during ritonavir treatment

1 reference

12 December 2020

A cohort study of nevirapine tolerance in clinical practice: French Aquitaine Cohort, 1997-1999.

1 reference

12 December 2020

Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group

1 reference

12 December 2020

Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy

1 reference

12 December 2020

Enhancement of hepatitis C virus replication and liver damage in HIV-coinfected patients on antiretroviral combination therapy

1 reference

12 December 2020

Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy

1 reference

12 December 2020

HIV-protease inhibitors

1 reference

12 December 2020

Hypersensitivity syndrome associated with zalcitabine therapy

1 reference

12 December 2020

Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection

1 reference

12 December 2020

The use of single-nucleotide polymorphism maps in pharmacogenomics

1 reference

12 December 2020

Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment

1 reference

12 December 2020

Short communication: liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection

1 reference

12 December 2020

Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy

1 reference

12 December 2020

Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease

1 reference

12 December 2020

Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy

1 reference

12 December 2020

Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?

1 reference

12 December 2020

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

12 December 2020

Severe hepatitis in three AIDS patients treated with indinavir

1 reference

12 December 2020

Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.

1 reference

12 December 2020

Direct analysis of mitochondrial toxicity of antiretroviral drugs

1 reference

12 December 2020

Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals

1 reference

12 December 2020

DRESS syndrome associated with nevirapine therapy

1 reference

12 December 2020

Hepatotoxicity after introduction of highly active antiretroviral therapy

1 reference

12 December 2020

Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial

1 reference

12 December 2020

Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome

1 reference

12 December 2020

Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART.

1 reference

12 December 2020

Cytokine-mediated hepatic apoptosis

1 reference

12 December 2020

Liver toxicity caused by nevirapine

1 reference

12 December 2020

Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens

1 reference

12 December 2020

Nevirapine-induced hepatitis treated with corticosteroids?

1 reference

12 December 2020

Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 fatal cases

1 reference

12 December 2020

Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group

1 reference

12 December 2020

Hepatomegaly with severe steatosis in HIV-seropositive patients

1 reference

12 December 2020

Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway

1 reference

12 December 2020

Mechanism of indinavir-induced hyperbilirubinemia

1 reference

12 December 2020

The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse

1 reference

12 December 2020

10.2165/00002018-200528010-00004

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1030515920

0 references

1 reference